Most men treated with radical prostatectomy or radiation therapy for localized prostate cancer will be cured of prostate cancer; however, some men will experience treatment failure.
Androgen deprivation therapy is well established in the treatment of metastatic prostate cancer. Adjuvant androgen deprivation therapy, following prostatectomy and/or radiotherapy, has been studied in the high-risk prostate cancer setting to try to reduce the risk of recurrence and improve patient outcomes. In this review, we discuss the current data for neoadjuvant and adjuvant therapy with androgen suppression, chemotherapy, and approaches with the newer hormonal agents.
Written by:
Lam ET, Glodé LM. Are you the author?
Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Mailstop 8117, 12801 East 17th Avenue, Aurora, CO 80045, USA.
Reference: Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204.
doi: 10.1016/j.hoc.2013.08.004
PubMed Abstract
PMID: 24188258
UroToday.com Prostate Cancer Section
